drugset / Trial / NCT04986995

OpicApone Sleep dISorder

NCT04986995

Phase 4 Completed 22 enrolled Bial - Portela C S.A.
NaSingle-groupOpen-labelTreatment

Summary

The aim of this study is to To investigate in an exploratory manner the efficacy of 50 mg opicapone when administered with the existing treatment of levodopa (L-dopa) plus a dopa decarboxylase inhibitor (DDCI), in Parkinson's disease (PD) patients with end-of-dose motor fluctuations and associated sleep disorders

Timeline

Start
2021-06-09
Primary completion
2023-03-29
Completion
2023-03-29

Drugs

EvaluationDrugModalityDoseRoute
Subject Opicapone Small molecule 50 mg Oral

Indications